Francesco Franchi is a Cardiology physician affiliated with University of Florida Health. OpenAlex indexes 225 publications with 5,818 citations (h-index 39); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
655 W 8th St
Acc Bldg, 5th Floor
Jacksonville, FL 322096511
Telephone
904-244-7772Registry record last updated 28 Sept 2015.
Clinical trials
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
Sponsor: University of Florida
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
Sponsor: University of Florida
- A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction
Sponsor: University of Florida
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Accriva Diagnostics Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20221 payment
- AstraZeneca Pharmaceuticals LPProgram year20213 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
83.9%Angiotensin receptor blocker (ARB)18.2%Losartan Potassium100%Part D≥12 patientsStatin18.2%Atorvastatin Calcium100%Part D≥13 patients+ 4 more classes in this area
Metabolism & gastrointestinal
8.4%SGLT2 inhibitor8.4%Jardiance100%Part D<11 patientsBlood & clotting
7.7%P2Y12 inhibitor7.7%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions
2024 - P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
Nature Reviews Cardiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
John Wingard, MD
University of Florida Health
Barry Byrne, MD
University of Florida Health
Gilbert Upchurch, MD
University of Florida Health
Carmen Allegra, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”